Literature DB >> 12523630

A clinical strain of Escherichia coli possessing CMY-2 plasmid-mediated amp C beta-lactamase: an emerging concern in pediatrics?

Claudia M Hoyen1, Andrea M Hujer, Kristine M Hujer, Steven H Marshall, Lenore Carias, Philip Toltzis, Louis B Rice, Robert A Bonomo.   

Abstract

A 5-year-old child was colonized by an isolate of Escherichia coli that transferred resistance to third-generation cephalosporins and cefoxitin. This resistance phenotype was encoded on a >75-kb plasmid pLRM 22. The transferable plasmid contained both blaCMY-2 and blaTEM-1b. Increasing reports of CMY-2 beta-lactamase in clinical isolates in children raise concerns about the empiric use of third-generation cephalosporins in this patient group.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12523630     DOI： 10.1089/10766290260469598

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN： 1076-6294            Impact factor:   3.431


  6 in total

1.  In vivo acquisition of high-level resistance to imipenem in Escherichia coli.

Authors:  Laurent Poirel; Claire Héritier; Colette Spicq; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.

Authors:  Marion J Skalweit; Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

3.  In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.

Authors:  William J Weiss; Peter J Petersen; Timothy M Murphy; Luanna Tardio; Youjun Yang; Patricia A Bradford; Aranapakam M Venkatesan; Takao Abe; Takeshi Isoda; Ado Mihira; Hideki Ushirogochi; Tsuyoshi Takasake; Steve Projan; John O'Connell; Tarek S Mansour
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  "Silent" dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast Ohio.

Authors:  Roberto A Viau; Andrea M Hujer; Steven H Marshall; Federico Perez; Kristine M Hujer; David F Briceño; Michael Dul; Michael R Jacobs; Richard Grossberg; Philip Toltzis; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

5.  Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

Authors:  Andrea Endimiani; Yohei Doi; Christopher R Bethel; Magdalena Taracila; Jennifer M Adams-Haduch; Alexandra O'Keefe; Andrea M Hujer; David L Paterson; Marion J Skalweit; Malcolm G P Page; Sarah M Drawz; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-02-09       Impact factor: 3.162

6.  Prevalence and mechanisms of broad-spectrum beta-lactam resistance in Enterobacteriaceae: a children's hospital experience.

Authors:  Xuan Qin; Danielle M Zerr; Scott J Weissman; Janet A Englund; Donna M Denno; Eileen J Klein; Phillip I Tarr; Justin Kwong; Jennifer R Stapp; Luis G Tulloch; Emmanouil Galanakis
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.